111 completed, 33 recruiting, 30 terminated, 28 unknown. 166 Phase 2, 56 Phase 1, 30 Phase 3, 14 Not applicable, 3 Early Phase 1.
Follow this drug Literature Review of Thiotepa trials Research Report on Thiotepa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| Thiotepa-Based Conditioning for Haploidentical Hematopoietic Stem Cell Transplantation in Older Patients With Severe Aplastic Anemia Thiotepa - Severe Aplastic Anemia, Hematopoietic Cell Transplant | Not yet recruiting | Peking University People's Hospital | 20 | 2026-09-20 | 2026-09-21 | |
| Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI. Thiotepa - Leptomeningeal Metastasis | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 50 | 2026-09-01 | 2026-08-21 |
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies Thiotepa, Fludarabine, Busulfan - Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | Sawa Ito, MD | 48 | 2026-07-27 | 2026-08-18 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission Thiotepa, Busulfan (BU), Fludarabine - Acute Myeloid Leukemia | Not applicable | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 93 | 2026-06-01 | 2026-05-04 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial Thiotepa and Melphalan, Melphalan - Multiple Myeloma | Not applicable | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 204 | 2026-04-20 | 2026-04-21 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse TEAM regimen (thiotepa, etoposide, cytarabine and melphalan) - Lymphoma Patients With High-risk of Central Nervous System Relapse | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-03-01 | 2026-03-19 |
| The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation Thiotepa, Fludarabine, G-CSF - Hematologic Malignancies | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-02-20 | 2026-03-02 |
| Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia TBF regimen - Chronic Myelomonocytic Leukemia (CMML) | Not applicable | Recruiting | Peking University People's Hospital | 31 | 2026-02-13 | 2026-09-15 |
| Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma Thiotepa, Pirtobrutinib , Sintilimab(TPS) - Pirtobrutinib, Sintilimab | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 24 | 2026-02-10 | 2026-02-18 |
| Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma Thiotepa - NK T-Cell Lymphoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 37 | 2025-12-30 | 2025-12-11 |
| TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-09-25 | 2026-06-02 |
| Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation Cytarabine IT, hydrocortisone, Cisplatin - CNS Embryonal Tumor, CNS, Medulloblastoma | Early Phase 1 | Recruiting | C17 Council | 15 | 2025-09-23 | 2026-07-14 |
| Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients Orelabrutinib, RCHOP+MTX or Thiotepa - CNS Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 23 | 2025-04-01 | 2025-03-30 |
| Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation Drugs Cyclophosphamide, Fludarabine, Thiotepa - Hematologic Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 35 | 2025-03-03 | 2026-04-28 |
Showing 20 of 243. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (54) · Leukemia, Myeloid, Acute (53) · Myelodysplastic Syndromes (47) · Leukemia (36) · Lymphoma, Non-Hodgkin (34) · Lymphoma (32) · Breast Neoplasms (29) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (25) · Central Nervous System Neoplasms (21) · Hematologic Neoplasms (20) · Hodgkin Disease (19) · Neuroblastoma (18) · Leukemia, Lymphocytic, Chronic, B-Cell (17) · Burkitt Lymphoma (15) · Multiple Myeloma (15)
Memorial Sloan Kettering Cancer Center (22) · Fred Hutchinson Cancer Center (20) · St. Jude Children's Research Hospital (15) · M.D. Anderson Cancer Center (14) · Children's Oncology Group (13) · Masonic Cancer Center, University of Minnesota (6) · Gustave Roussy, Cancer Campus, Grand Paris (5) · Herbert Irving Comprehensive Cancer Center (5) · Paul Szabolcs (5) · NYU Langone Health (4) · National Cancer Institute (NCI) (4) · Roswell Park Cancer Institute (4) · Samsung Medical Center (4) · St. Anna Kinderkrebsforschung (4) · City of Hope Medical Center (3)
United States (170) · Canada (21) · Australia (18) · China (14) · France (14) · Italy (12) · Germany (11) · Netherlands (9) · United Kingdom (9) · New Zealand (8) · Switzerland (8) · Austria (7) · Czechia (6) · Sweden (6) · Israel (5)
Brandon Triplett, MD (8) · Jonathan L. Finlay, MB, ChB (4) · Marie Bleakley (4) · Paul Szabolcs, MD (4) · Charles S. Hesdorffer, MD (3) · Filippo Milano (3) · Leona A. Holmberg, MD, PhD (3) · Philip L. McCarthy, MD (3) · William I. Bensinger, MD (3) · Andrew L. Pecora, MD, FACP (2) · Ashish Gupta, MBBS, MPH (2) · Brian Shaffer, MD (2) · Farid Boulad, MD (2) · George Somlo, MD (2)
PMID 33242441, PMID 35007144, PMID 15812540, PMID 21195303, PMID 25753432, PMID 10797354, PMID 16809737, PMID 16966258, PMID 17404368, PMID 17563739, PMID 18037940, PMID 19660720, PMID 20684990, PMID 21636711, PMID 21976674, PMID 22491731, PMID 23242601, PMID 23416850, PMID 24296492, PMID 24497539, PMID 24969797, PMID 25568347, PMID 25605857, PMID 25687795, PMID 25742699, PMID 25760637, PMID 25862561, PMID 25937263, PMID 26053664, PMID 26254812, PMID 26346136, PMID 26569093, PMID 26869630, PMID 26869631, PMID 27132696, PMID 27243412, PMID 27325334, PMID 27476790, PMID 27863192, PMID 28472509, PMID 28511709, PMID 28559537, PMID 29054815, PMID 29189665, PMID 29307718, PMID 29769208, PMID 30953028, PMID 31319153, PMID 31454045, PMID 31545689
U10CA180886 (9), P30CA015704 (6), U10CA098543 (6), P01CA018029 (5), P30CA008748 (4), 2009 (3), P30CA033572 (3), P30CA016056 (2), P30CA016672 (2), P50HL110787 (2), R01HL121568 (2), 2014 (1), 2015 (1), 2019 (1), K23CA154532 (1)